Stockwinners Market Radar for May 19, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:26 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Alphabet's Google (GOOG; GOOGL) has suspended business with Huawei that requires the transfer of hardware and software products except those covered by open source licenses in a blow to the Chinese technology company that the U.S. government has sought to blacklist around the world, according to Reuters, citing a source familiar with the matter. Huawei Technologies will immediately lose access to updates to the Android operating system, and the next version of its smartphones outside of China will also lose access to popular applications and services including the Google Play Store and Gmail app, the report noted. 2. African swine fever, harmless to humans but deadly to pigs, has decimated Chinese hog counts, constraining supplies in the world's top market for pork, and McDonald's (MCD) and Tyson (TSN) are among companies that expect tighter supplies of pork and bacon to result in more-expensive meat globally, The Wall Street Journal's Heather Haddon and Jacob Bunge reported. 3. Nordstrom (JWN) remains the best-positioned retailer in the tough department store sector, with a mix of full-price and discount stores, a pioneering online presence and a reputation for superior service and affluent customers, Andrew Bary wrote in this week's edition of Barron's. Investor worries include a disappointing Christmas selling season and potential tariffs on Chinese-made clothing and shoes, but that seems already discounted in the stock, the author noted, adding that Nordstrom's generous dividend looks secure, given that the company pays outs just 40% of its earnings. 4. Disney (DIS) and Marvel's "Avengers: Endgame" reign has come to an end after three weekends at the top of the domestic box office. Winning the weekend, Lionsgate's (LGF.A) "John Wick: Chapter Three - Parabellum" earned $57.2M in its debut from 3,850 theaters. The movie sports an A- CinemaScore and an 88% Rotten Tomatoes score. Overseas, "Parabellum" earned $35.2M from 66 international markets. 5. Applied Materials (AMAT), BorgWarner (BWA), Charles Schwab (SCHW), Regeneron Pharmaceuticals (REGN), Tapestry (TPR) and Take-Two (TTWO) saw positive mentions in this week's edition of Barron's.

16:07 EDT ResMed reveals demographic, clinical factors affect adherence to PAP therapy - ResMed revealed several demographic and clinical factors affect adherence to PAP - positive airway pressure - therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International Conference. The study found significant differences in one-year adherence between people of different ages and disease severity levels: Men with sleep apnea are 8.5 percentage points more likely to stay adherent on PAP therapy than women. People over age 60 were 7.3 percentage points more adherent than the entire study cohort. People with self-reported severe sleep apnea were 78% adherent at the one-year mark, compared to 70.5% of those with self-reported moderate sleep apnea, and 65.2% of those with mild sleep apnea. medXcloud, a ResMed-assembled group of healthcare key opinion leaders, conducted the study, which examined de-identified data of 1,063,870 U.S. PAP users from ResMed's world-leading remote monitoring network, AirView. PAP users must have also been registered for the myAir patient engagement tool.

12:44 EDT Acadia presents Phase 2 CLARITY results for Pimavanserin - Acadia Pharmaceuticals presented data from its Phase 2 CLARITY study, which evaluated the efficacy, safety, and tolerability of pimavanserin as an adjunctive treatment for major depressive disorder at the 2019 American Psychiatric Association Annual Meeting. The Phase 2 CLARITY study was a 10-week, randomized, double-blind, placebo-controlled, multi-center, two-stage sequential parallel comparison design study that evaluated the efficacy, safety, and tolerability of pimavanserin. Pimavanserin was administered as an adjunctive treatment in patients with MDD who had an inadequate response to a stable dose of standard antidepressant therapy with either a selective serotonin reuptake inhibitor or a serotonin norepinephrine reuptake inhibitor. The study randomized 207 patients across 27 clinical research centers in the U.S. and was conducted in collaboration with the Massachusetts General Hospital Clinical Trials Network and Institute. In the trial, pimavanserin met the overall primary endpoint of the weighted average results of Stage 1 and Stage 2 by significantly reducing the 17-item Hamilton Depression Rating Scale total score compared to placebo. On the key secondary endpoint, pimavanserin demonstrated statistically significant reductions compared to placebo in the Sheehan Disability Scale score. Positive results were also observed for seven other secondary endpoints, including improvement in daytime sleepiness as measured by the Karolinska Sleepiness Scale and improvement in sexual function as measured by the Massachusetts General Hospital Sexual Functioning Index. On April 25, ACADIA announced it had initiated its Phase 3 CLARITY program for pimavanserin as an adjunctive treatment for MDD. The CLARITY-2 study will be based in the U.S. and has already initiated enrollment and the CLARITY-3 study will be based outside the U.S. and will initiate enrollment in the upcoming months. Both studies are six-week, parallel-designed, randomized, double-blind, placebo-controlled, multi-center studies designed to evaluate the efficacy and safety of pimavanserin as adjunctive treatment in patients with MDD who have an inadequate response to standard antidepressant therapy with either a SSRI or a SNRI.